Item 15. Exhibits and Financial Statement Schedules
37K characters. Original on sec.gov · Markdown
Item 15. Exhibits and Financial Statement Schedules
A. Documents filed as part of this report:
- Financial Statements:
The following financial statements are incorporated by reference from our Annual Report to Stockholders for the fiscal year ended December 31, 2017, as provided in Item 8 hereof:
| Consolidated Statements of Income for the Years Ended December 31, 2017, 2016 and 2015 | |
|---|---|
| Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2017, 2016 and 2015 | |
| Consolidated Balance Sheets as of December 31, 2017 and 2016 | |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016 and 2015 | |
| Consolidated Statements of Shareholders’ Equity for the Years Ended December 31, 2017, 2016 and 2015 | |
| Notes to Consolidated Financial Statements | |
| Report of Independent Registered Public Accounting Firm |
- Financial Statement Schedules
All financial statement schedules are omitted because they are not applicable, not required under the instructions, or the information is included in the consolidated financial statements or related notes.
B. Exhibits
Exhibits marked with an asterisk (*) are hereby incorporated by reference to exhibits or appendices previously filed by the Registrant as indicated in brackets following the description of the exhibit.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| CVS HEALTH CORPORATION | ||
|---|---|---|
| Date: February 14, 2018 | By: | /s/ DAVID M. DENTON |
| David M. Denton | ||
| Executive Vice President and Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title(s) | Date | ||
| /s/ RICHARD M. BRACKEN | Director | February 14, 2018 | ||
| Richard M. Bracken | ||||
| /s/ C. DAVID BROWN II | Director | February 14, 2018 | ||
| C. David Brown II | ||||
| /s/ EVA C. BORATTO | Executive Vice President - Controller and | February 14, 2018 | ||
| Eva C. Boratto | Chief Accounting Officer | |||
| (Principal Accounting Officer) | ||||
| /s/ ALECIA A. DECOUDREAUX | Director | February 14, 2018 | ||
| Alecia A. DeCoudreaux | ||||
| /s/ DAVID M. DENTON | Executive Vice President and Chief | February 14, 2018 | ||
| David M. Denton | Financial Officer (Principal Financial | |||
| Officer) | ||||
| /s/ NANCY-ANN M. DEPARLE | Director | February 14, 2018 | ||
| Nancy-Ann M. DeParle | ||||
| /s/ DAVID W. DORMAN | Chairman of the Board and Director | February 14, 2018 | ||
| David W. Dorman | ||||
| /s/ ANNE M. FINUCANE | Director | February 14, 2018 | ||
| Anne M. Finucane | ||||
| /s/ LARRY J. MERLO | President and Chief Executive Officer | February 14, 2018 | ||
| Larry J. Merlo | (Principal Executive Officer) and | |||
| Director | ||||
| /s/ JEAN-PIERRE MILLON | Director | February 14, 2018 | ||
| Jean-Pierre Millon | ||||
| /s/ MARY L. SCHAPIRO | Director | February 14, 2018 | ||
| Mary L. Schapiro | ||||
| /s/ RICHARD J. SWIFT | Director | February 14, 2018 | ||
| Richard J. Swift | ||||
| /s/ WILLIAM C. WELDON | Director | February 14, 2018 | ||
| William C. Weldon | ||||
| /s/ TONY L. WHITE | Director | February 14, 2018 | ||
| Tony L. White |
Previous: Item 14. Principal Accountant Fees and Services